Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Takeda Licenses AMAG’s Anemia Drug
by Jean-François Tremblay
April 12, 2010
| A version of this story appeared in
Volume 88, Issue 15
Takeda Pharmaceutical will pay up to $280 million for the rights to sell a new kidney drug in Europe, Canada, the former Soviet Union, Turkey, and Asian countries excluding China and Japan. Feraheme, known generically as ferumoxytol, was developed by Amag Pharmaceuticals of Lexington, Mass., and approved in the U.S. last year for the intravenous treatment of iron-deficiency anemia. Takeda will make an initial payment of $60 million to Amag, followed by payments of up to $220 million for reaching certain milestones.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter